Targeted opening of the blood–brain barrier facilitates doxorubicin/anti-PD-1-based chemoimmunotherapy of glioblastoma

Jonathan G. Pol, Manuela Lizarralde-Guerrero, Andrea Checcoli, Guido Kroemer

    Résultats de recherche: Contribution à un journal!!Comment/debate

    Résumé

    Doxorubicin is a prototypical inducer of immunogenic cell death (ICD) that sensitizes to subsequent immunotherapy by PD-1 blockade. However, this systemic drug combination fails against glioblastoma, hidden behind the blood–brain barrier (BBB). A recent work delineates a biophysical method for BBB permeabilization that yields effective preclinical effects of chemoimmunotherapy.

    langue originaleAnglais
    Numéro d'article2385124
    journalOncoImmunology
    Volume13
    Numéro de publication1
    Les DOIs
    étatPublié - 1 janv. 2024

    Contient cette citation